Nelson Advisors: Strategic Patent Litigation in the Wearables Market - Analysis of Oura Ring v UltraHuman and SVTronics
The smart ring category has evolved from an experimental subsegment of personal wellness hardware into a fiercely contested consumer technology sector. On October 22nd, 2026, market pioneer Ouraring Inc. escalated its long-running intellectual property offensive against Bengaluru-based challenger Ultrahuman by filing a patent infringement complaint in the U.S. District Court for the Eastern District of Texas. The lawsuit targets Ultrahuman’s redesigned flagship wearable, the Ring Pro, asserting that the device infringes both an ornamental design patent and a utility patent covering internal component architecture.
This action follows the exclusion of Ultrahuman’s earlier Ring Air model by the U.S. International Trade Commission (ITC), an enforcement action that temporarily cleared the domestic market for Oura.
By naming Texas-based electronics manufacturing services provider SVTronics, Inc. as a direct co-defendant, Oura has targeted not only Ultrahuman's overseas corporate entities, but also the domestic contract manufacturing framework Ultrahuman established to restore its commercial footprint in the United States.
Federal Action and Procedural Landscape
The complaint, captioned Ouraring Inc. v. Ultrahuman Healthcare Inc. et al. (Civil Action No. 2:2026cv00953), was initiated on October 22nd, 2026, in the Marshall Division of the Eastern District of Texas. The case was assigned to Chief District Judge Rodney Gilstrap and referred to Magistrate Judge Roy S. Payne. Oura simultaneously demanded a trial by jury. The Eastern District of Texas remains a premier domestic venue for patent enforcement actions due to its established local patent rules, predictable trial management schedules, and expedited progression toward jury trials.
The complaint names three corporate defendants: Ultrahuman Healthcare Inc., the Delaware-incorporated commercial entity operating in the United States; Ultrahuman Healthcare Pvt. Ltd., the parent company based in Bengaluru, India; and SVTronics, Inc., an electronics manufacturing services company headquartered in Plano, Texas. The causes of action are rooted in 35 U.S.C 271, alleging direct infringement under subsection (a), active inducement under subsection (b), and contributory infringement under subsection (c). Oura asserts that the defendants have systematically infringed and continue to infringe valid patent claims through the unauthorized domestic manufacture, importation, assembly, marketing and commercial distribution of the Ultrahuman Ring Pro.
Oura’s prayer for relief seeks preliminary and permanent injunctive relief barring all named defendants, their contract manufacturing partners, and affiliated distribution networks from manufacturing, importing, using, marketing, or selling the Ring Pro within the United States. In addition to injunctive relief, Oura requests an award of compensatory monetary damages adequate to compensate for past and ongoing infringement, in an amount no less than a reasonable royalty, together with pre- and post-judgment interest. Oura also seeks treble damages under 35 U.S.C. 284, asserting that the defendants acted with objective recklessness and willful intent by commercialising an infringing architecture despite prior administrative enforcement proceedings, alongside a request for attorneys' fees under 35 U.S.C. 285.
This filing follows earlier federal proceedings between related corporate entities, such as Ouraring, Inc. v.
Ultrahuman Healthcare LLC et al. (Civil Action No. 2:2025cv00928), which Judge Gilstrap scheduled for a July 2027 pretrial conference. The October 2026 action represents an aggressive expansion of Oura's offensive strategy by introducing newly issued utility claims explicitly drafted to cover current-generation hardware packaging.
Technological Architecture and Asserted Patent Claims
Oura’s claims rest on two distinct instruments within its intellectual property portfolio: an early design patent directed to exterior industrial form factor, and a utility patent directed to the dense spatial packing of internal electrical, power, and physiological sensing systems within an annular ring body.
Metric / Parameter | U.S. Patent No. D804,471 | U.S. Patent No. 12,769,363 |
Patent Classification | Design (Ornamental Ring Geometry) | Utility (Wearable Computing Device) |
Issue Date | December 5, 2017 | October 20, 2026 |
Lead Inventors | Curt C. von Badinski et al. | Curt C. von Badinski, Michael J. Strasser, Peter Twiss |
Prosecution Lineage | Motiv, Inc. → Proxy, Inc. → Ouraring Inc. | Motiv, Inc. → Proxy, Inc. → Ouraring Inc. |
Asserted Scope | Non-functional, ornamental exterior casing profile | Interior integration of curved battery, PCB, magnets, and sensors |
Legal Infringement Test | "Ordinary Observer" Standard (Egyptian Goddess) | Literal Infringement and Doctrine of Equivalents |
U.S. Design Patent No. D804,471 ('471), granted on December 5, 2017, protects the ornamental configuration of a wearable electronic ring. Originally developed by the engineering leadership at smart ring startup Motiv, Inc., the patent claims the exterior visual features of a finger-worn device, including its annular contour, cross-sectional curvature, and outer-to-inner perimeter transitions.
Under federal design patent doctrine established in Gorham Co. v. White and clarified by the Federal Circuit in Egyptian Goddess, Inc. v. Swisa, Inc., infringement requires demonstrating that an ordinary observer, giving the attention typical of a retail purchaser, would find the overall ornamental appearance of the accused device substantially similar to the patented design, inducing purchase under mistaken identity. Oura alleges that the exterior aesthetic surfaces of the Ultrahuman Ring Pro deliberately mimic the visual balance and outer geometry claimed in the '471 patent, thereby confusing consumer perception.
The technological core of the lawsuit lies in U.S. Utility Patent No. 12,769,363 ('363), titled "Wearable computing device," which was granted by the U.S. Patent and Trademark Office on Tuesday, October 20th, 2026—just two days prior to Oura filing its complaint. The '363 patent originates from the foundational wearable computing portfolio originally developed by Motiv and later transferred through Proxy, Inc., before being acquired by Oura in 2023. Through continuation applications prosecuted under 35 U.S.C. 120, Oura preserved active pendency from the original priority filings, enabling its patent attorneys to capture the mechanical and electrical spatial trade-offs required to miniaturize health tracking hardware.
The asserted claims of the '363 patent address the structural layout necessary to house computational elements inside an ultra-compact ring without adding excessive bulk. The patent claims an annular housing that integrates a curved, semi-flexible electrochemical cell contoured along the inner circular boundary of the band to maximize volumetric energy density while ensuring uniform weight distribution around the finger.
Within this internal envelope, the patent defines a flexible printed circuit board (PCB) that routes power, data conduits, and microcontroller signals alongside internal magnetic elements designed for wireless dock alignment and automated orientation. The claims also encompass the placement of photoplethysmography (PPG) sensor modules on the inner circumference, where light-emitting diodes and optical detectors interface directly with the palmar digital arteries to continuously capture cardiovascular metrics.
Because the '363 patent issued in late October 2026, it represents fresh intellectual property that was completely insulated from earlier ITC administrative records and Customs classification rulings.
Administrative Precedents: The ITC Exclusion and CBP Part 177 Clearance
The current district court dispute represents the second phase of a multi-year intellectual property campaign between Oura and Ultrahuman across federal and administrative venues. In March 2024, Oura initiated Investigation No. 337-TA-1398 before the U.S. International Trade Commission, alleging that several international competitors, including Ultrahuman and RingConn, were importing smart wearables that infringed several of its patents.
On August 21, 2025, the ITC issued a Final Determination confirming a violation of Section 337 of the Tariff Act of 1930. The Commission determined that Ultrahuman’s flagship commercial product, the Ring Air, infringed valid claims of U.S. Patent No. 11,868,178 (the '178 patent). The ITC issued a Limited Exclusion
Order directing border officials to bar infringing devices from entering the United States, alongside Cease
and Desist Orders prohibiting domestic marketing, inventory distribution, and commercialization. This forced Ultrahuman to withdraw the Ring Air from the American market.
To circumvent the ITC exclusion order, Ultrahuman redesigned its hardware platform, announcing the Ring Pro in February 2026. The company replaced the internal resin encapsulation of the Ring Air with a structural unibody titanium cylinder, integrated a dual-core processor, and reconfigured the battery subsystem to achieve a 15-day operational lifespan. Ultrahuman subsequently submitted this redesigned Ring Pro to the U.S. Customs and Border Protection Regulations and Rulings Directorate under 19 C.F.R. Part 177, requesting an administrative ruling that the new model avoided the claims of the '178 patent and fell outside the scope of the ITC exclusion order.
In March 2026, CBP issued an administrative determination confirming that the redesigned Ring Pro did not infringe the patent adjudicated in the Section 337 investigation, permitting the device to clear customs. Ultrahuman subsequently initiated domestic pre-orders on March 24, 2026, and commenced retail shipments on June 20, 2026, at a $479 retail price point.
The Eastern District of Texas complaint directly challenges the commercial protection offered by this CBP clearance. While Ultrahuman relies on the Customs ruling as evidence of non-infringement, CBP administrative rulings are legally limited in scope. An administrative ruling under 19 C.F.R. Part 177 evaluates solely whether an article falls within the scope of an existing ITC remedial order directed toward specifically adjudicated claims. Customs officers have no jurisdiction or statutory authority to determine infringement of newly issued patents that were never part of the underlying administrative investigation.
By asserting the design patent D804,471 and the freshly issued utility patent 12,769,363, Oura established an independent cause of action in federal district court. The March 2026 customs clearance insulates the Ring Pro from summary border interdiction under the old ITC order, but it provides no defense against a standalone patent infringement suit in an Article III forum.
Contract Manufacturing Exposure: SVTronics and the Plano Facility
A key tactical development in the Texas complaint is the naming of SVTronics, Inc. as a direct co-defendant alongside Ultrahuman. SVTronics is a precision electronics manufacturing services provider established in 1996 with operations in Plano, Texas. To address supply chain risks, hedge against escalating tariffs on foreign-assembled electronics, and circumvent border-level ITC exclusion orders, Ultrahuman partnered with SVTronics to establish a domestic production facility known as the "UltraFactory" inside SVTronics' Plano facility.
Operational since late 2024, the Plano plant expanded throughout 2025 with the objective of scaling production capacity to 500,000 smart rings per year, enabling Ultrahuman to fulfill domestic demand with American-manufactured units. Domestic assembly offered significant strategic advantages by allowing finished goods to enter retail channels without passing through international shipping ports subject to customs holds.
Oura countered this strategy by invoking 35 U.S.C. § 271(a), which establishes direct liability for any entity that unauthorizedly "makes, uses, offers to sell, or sells any patented invention within the United States". Under federal patent jurisprudence, contract manufacturers enjoy no immunity simply because they assemble hardware under the direction and specifications of a commercial client.
If the finished hardware produced on an assembly line embodies every limitation of an asserted patent claim, the contract assembler is directly liable for patent infringement. Oura asserts that SVTronics directly infringes by assembling, soldering, potting, and testing the Ring Pro hardware in Plano, while Ultrahuman remains liable under 35 U.S.C. § 271(b) for actively directing and inducing those manufacturing operations.
Naming SVTronics also provides Oura with a procedural advantage regarding venue. Following the Supreme Court’s decision in TC Heartland LLC v. Kraft Foods Group Brands LLC, patent plaintiffs in domestic infringement actions must satisfy the requirements of 28 U.S.C. § 1400(b), which limits venue to districts where a defendant resides or where it has committed acts of infringement and maintains a regular, established place of business. While foreign corporations like Ultrahuman Healthcare Pvt. Ltd. may be sued
in any judicial district pursuant to 28 U.S.C. § 1391(c)(3), foreign corporate defendants frequently seek to transfer cases to jurisdictions such as the Northern District of California.
Because SVTronics maintains physical corporate headquarters and active assembly plants in Plano, Texas—located within the Eastern District—its inclusion as a primary manufacturer establishes proper venue under § 1400(b), preventing Ultrahuman from transferring the dispute to another forum.
Corporate Assertions and Market Defences
The positions taken by both companies reflect contrasting narratives regarding intellectual property enforcement and technological development in the consumer electronics sector. Oura frames the litigation as the defense of its foundational research and development against serial design replication. In an official corporate statement, an Oura spokesperson asserted:
"Ultrahuman has a history of copying Oura’s innovations, as demonstrated by the 2025 ITC ruling against the company. Ultrahuman introduced a redesigned ring but failed to address continued infringement of Oura’s patents, seeking instead to capitalize on our innovation and the market leadership we have built."
Oura’s legal posture maintains that surface-level modifications—such as shifting from an internal resin core to a titanium unibody casing—do not cure infringement when the overall package continues to utilize the curved battery architecture, magnetic charging geometry, and optical sensor configurations claimed in Oura's utility portfolio.
Conversely, Ultrahuman CEO and co-founder Mohit Kumar publicly stated that the Ring Pro remains available across domestic retail and direct-to-consumer channels without commercial restriction. Ultrahuman’s executive leadership highlighted that no federal court has issued an injunction, preliminary restraining order, or finding of liability against the Ring Pro.
Ultrahuman's legal defense relies on its administrative victory before CBP, arguing that the Ring Pro was developed through substantial engineering investment to create an independent hardware architecture. The company also criticized the timing of the lawsuit, noting that Oura's assertion of a patent issued only 48 hours prior suggests a calculated attempt to use litigation to disrupt retail distribution rather than protect organic innovation. Ultrahuman confirmed that it will contest Oura's claims through the appropriate judicial channels while keeping its domestic manufacturing and retail distribution active.
Industry Litigation Landscape and Category Dynamics
The lawsuit against Ultrahuman and SVTronics is part of a coordinated intellectual property campaign that Oura has deployed across the global smart wearables sector. As consumer demand shifted from wrist-worn fitness bands toward discreet smart rings, Oura used its patent holdings to build a defensive perimeter around the category.
Competitor / Enterprise | Forum / Administrative Action | Patents & Claims Asserted | Procedural Resolution / Commercial Status |
Ultrahuman | ITC Inv. No. 337-TA-1398; E.D. Tex. (2:2025cv00928, 2:2026cv00953) | U.S. Patent Nos. 11,868,178; D804,471; 12,769,363 | LEO issued against Ring Air; Ring Pro sued post-CBP clearance |
RingConn | ITC Inv. No. 337-TA-1398 | Multi-claim utility patent assertion on ring architecture | Settled via multi-year, royalty-bearing licensing agreement |
Circular | U.S. District Court Infringement Actions | Hardware packaging and haptic notification architecture | Settled via multi-year, royalty-bearing licensing agreement |
Zepp Health (Amazfit) | U.S. District Court Patent Assertions | Health-sensing miniaturization and data extraction patents | Ongoing licensing negotiations and active docket tracking |
Samsung Electronics | N.D. Cal. (Declaratory Judgment); ITC Inv. No. 337-TA-1468 | Preemptive non-infringement claims on Galaxy Ring; Oura Section 337 counter-complaint | Active administrative and federal litigation |
The business motivations underlying Oura's enforcement strategy stem from the market concentration of the wearables sector. The United States remains the primary geographic market for high-margin smart wearables, accounting for approximately 60% of worldwide volume. Market projections indicate that the smart ring segment will sustain double-digit shipment growth, expanding by 12.8%.
The practical impact of Oura’s IP enforcement was demonstrated when the ITC instituted its import ban against the Ultrahuman Ring Air in late 2025. In the second quarter of 2024, Ultrahuman held an estimated 25% share of the U.S. smart ring market. Following the ITC exclusion order and subsequent product withdrawal, Ultrahuman's domestic market share declined precipitously.
During that same window, Oura consolidated its market position, expanding its domestic share from 63% to 85%. The ability to exclude competitors or impose margin-diluting licensing royalties protects Oura's market share and subscription-driven revenue model as the company prepares for an initial public offering.
Ultrahuman, however, possesses the capital resources necessary to mount an extended defense. In September 2026, the company completed a $70 million financing round consisting of $65 million in equity and $5 million in debt, led by Qualcomm Ventures and healthcare diagnostic provider Labcorp, alongside Alpha Wave and Blume Ventures.
The funding round valued the startup at $365 million and supports joint engineering initiatives with Qualcomm to integrate advanced edge-compute processing directly into future smart ring hardware. This institutional backing suggests that Ultrahuman’s investors are willing to fund legal expenses in federal court to preserve access to the North American market.
Strategic Implications and Future Trajectory
The complaint filed in the Eastern District of Texas initiates a multi-stage litigation process that will influence supply chain structures and competitive dynamics throughout the consumer health technology industry. Several legal, procedural, and commercial factors will determine the trajectory of the dispute over the coming quarters.
In the initial phase of the litigation, Oura may pursue a preliminary injunction to halt domestic assembly and distribution of the Ring Pro prior to trial. To secure preliminary injunctive relief, Oura must satisfy the four-factor test articulated by the Supreme Court in eBay Inc. v. MercExchange, L.L.C., proving a likelihood of success on the merits, irreparable harm in the absence of immediate court intervention, a balance of equities tipping in its favor, and alignment with the public interest.
Because Chief Judge Gilstrap typically prioritizes rapid trial dates over preliminary injunctions, Ultrahuman may keep the Ring Pro on domestic shelves while discovery progresses, preventing the immediate revenue losses it suffered during the earlier ITC exclusion.
Concurrently, Ultrahuman’s defense team is expected to initiate administrative counter-challenges by petitioning the Patent Trial and Appeal Board (PTAB) for Inter Partes Review (IPR) against U.S. Patent No. 12,769,363. Ultrahuman will likely argue that assembling curved batteries, printed circuits, and optical sensor arrays inside an annular ring casing represents an obvious evolution of prior art disclosed across academic literature and wearable filings dating back to 2013. If the PTAB institutes review, Ultrahuman could seek a stay of the Texas district court proceedings, though the Eastern District often declines to pause litigation pending PTAB outcomes when cases are nearing trial.
The inclusion of SVTronics adds complex contractual dynamics to the litigation. SVTronics must either rely on the indemnification provisions of its contract manufacturing agreements with Ultrahuman or retain independent counsel to protect against direct liability under 35 U.S.C. § 271(a). If the litigation imposes significant discovery burdens, deposition demands, and potential monetary exposure on SVTronics, it could establish a precedent that causes domestic electronics manufacturing services providers to re-evaluate assembling consumer wearables subject to active patent disputes.
The ultimate resolution will likely involve a commercial choice between an expensive jury trial and a negotiated licensing structure. Oura’s past disputes with competitors RingConn and Circular ended in settlements featuring multi-year, royalty-bearing licenses that allowed both companies to continue domestic sales in exchange for per-unit royalty payments. While Ultrahuman’s $70 million capital raise provides the financial runway to mount an extensive invalidity and non-infringement defense, an adverse claim construction ruling during the Markman hearing or a finding of willful infringement could threaten its core business.
If the court rejects Ultrahuman's design-around arguments, the company will face the choice of paying licensing royalties that dilute its hardware margins or risking a permanent injunction that bars both domestic assembly and consumer sales across the United States.
Nelson Advisors > European Healthcare Technology Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions for European HealthTech, MedTech, Digital Health, Healthcare IT, Healthcare AI companies in the Lower to Mid Market ranging from $25M to $250M EV. www.nelsonadvisors.co.uk
Healthcare.Digital is the Google News approved HealthTech and MedTech Thought Leadership platform for Nelson Advisors, positioning them as a specialised authority on European Healthcare Technology M&A and strategic corporate development. https://www.healthcare.digital
Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Meet Nelson Advisors @ Events in 2026
Digital Health Rewired > March 2026 > Birmingham, UK
NHS ConfedExpo > June 2026 > Manchester, UK
HLTH Europe > June 2026, Amsterdam, Netherlands
HIMSS AI in Healthcare > July 2026, New York, USA
Bits & Pretzels > September 2026, Munich, Germany
HealthInvestor Healthcare Summit > September 2026, London, UK
World Health Summit 2026 > October 2026, Berlin, Germany
HLTH USA 2026 > October 2026, USA
Global Health Exhibition 2026 > October 2026, Riyadh, Saudi Arabia
Web Summit 2026 > November 2026, Lisbon, Portugal
MEDICA 2026 > November 2026, Düsseldorf, Germany
Leaders in Health Summit 2026 > November 2026, London, UK
Venture Capital World Summit > December 2026, Toronto, Canada
Meet Nelson Advisors @ Events in 2027
Digital Health Rewired > March 2027 > Birmingham, UK
Barclays Health Elevate > March 2027, London, UK
NHS ConfedExpo > June 2027 > Manchester, UK
HLTH Europe > June 2027, Amsterdam, Netherlands
Comments